CaffeineCAF+OLDNCT07711665
Acute Caffeine Intake in Older Adults
A study testing Caffeine in people with Caffeine and Placebo - Control, run by University of Alcala at 1 site in Spain.
Trial summary
Evidence regarding the ergogenic effects of caffeine is well-established in young adults, but evidence in older adults remains scarce, particularly during dynamic resistance exercise. Read more about this study
- Who is it for?
- Ages 55 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Caffeine, Placebo - Control
- What is being tested?
- Caffeine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteSpain
- Study dates
- 10 Jan 2024to 24 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 55 years.
- Body mass index (BMI) lower than 25 kg/m².
- Physically active subjects (≥150 min/week of moderate exercise).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
- Participants capable of performing the tests.
Who cannot join
- History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
- Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
- Body mass index (BMI) ≥ 25 kg/m².
- Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. • Performing strenuous exercise within 48 hours prior to the tests.
- Failing to replicate the same food intake on the two experimental days.
- Consuming caffeine after 6 PM on the day prior to training or testing.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, 28805
About this study
Official title: Acute Caffeine Intake Effects in Strength and Endurance Performance in Resistance-training-naïve Older Adults
Evidence regarding the ergogenic effects of caffeine is well-established in young adults, but evidence in older adults remains scarce, particularly during dynamic resistance exercise. Therefore, this study investigated the effects of acute caffeine ingestion on upper- and lower-body muscular strength and endurance performance, as well as the influence of sex and CYP1A2 genotype, in healthy resistance training-naïve older adults.
- Conditions
- Caffeine, Placebo - Control
- Being tested
- Caffeine, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CaffeineDietary supplement
Acute caffeine intake (3 mg/kg)
PlaceboDietary supplement
Placebo (3 mg/kg maltodextrin)
| Study group | Role | What they receive |
|---|---|---|
| Caffeine | Experimental | Acute caffeine intake (3 mg/kg) Receives: Dietary Supplement: Caffeine |
| Placebo | Placebo comparator | Placebo (3 mg/kg maltodextrin) Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean velocity at different %1RM
Mean velocity at different %1RM
Measured: Through study completion, an average of 3 weeks
Number of repetitions performed during 1 set at 65%1RM until task failure
In bench press and back squat exercises
Measured: Through study completion, an average of 3 weeks
Bar velocity deplacement performed in 1 set at 65%1RM until task failure
In bench press and back squat exercises
Measured: Through study completion, an average of 3 weeks
handgrip and isometric mid-thigh pull tests
N generated
Measured: Through study completion, an average of 3 week
Secondary outcomes (3)
CYP1A2 polymorphism
Using saliva sample and PCR
Measured: Before the beginning of the trial
Mood state (tension, depression, anger, vigor, fatigue and confusion)
Participants graded a set of 29 items related to the mood on a Likert scale from 0 (not at all) to 4 (extremely) in reply to the question: How do you feel at this moment? to assess six scales: tension, depression, anger, vigor, fatigue and confusion.
Measured: Through study completion, an average of 3 weeks
Adverse effects
perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort
Measured: Through study completion, an average of 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start10 Jan 2024
- Primary completion21 Dec 2025
- Study completion24 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CaffeineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alcala
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alberto Pérez-López, University of Alcala
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07711665
- Sponsor's protocol ID
- CEIP/2022/3/055_1
- Acronym
- CAF+OLD
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Caffeine Intake Effects in Strength and Endurance Performance in Resistance-training-naïve Older Adults
- ClinicalTrials.gov ID
- NCT07711665
- Acronym / sponsor ID
- CAF+OLD / CEIP/2022/3/055_1
- Conditions
- Caffeine, Placebo - Control
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- University of AlcalaUniversity, hospital or other
- Study start
- 10 Jan 2024 (actual)
- Primary completion
- 21 Dec 2025 (actual)
- Study completion
- 24 Apr 2026 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evidence regarding the ergogenic effects of caffeine is well-established in young adults, but evidence in older adults remains scarce, particularly during dynamic resistance exercise. Therefore, this study investigated the effects of acute caffeine ingestion on upper- and lower-body muscular strength and endurance performance, as well as the influence of sex and CYP1A2 genotype, in healthy resistance training-naïve older adults.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Caffeine | Experimental | Dietary Supplement: CaffeineAcute caffeine intake (3 mg/kg) |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo (3 mg/kg maltodextrin) |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 55 years.
- Body mass index (BMI) lower than 25 kg/m².
- Physically active subjects (≥150 min/week of moderate exercise).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
- Participants capable of performing the tests.
Key exclusion criteria (6 listed)
- History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
- Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
- Body mass index (BMI) ≥ 25 kg/m².
- Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. • Performing strenuous exercise within 48 hours prior to the tests.
- Failing to replicate the same food intake on the two experimental days.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CaffeineAcute caffeine intake (3 mg/kg) | Dietary supplement | Caffeine |
| PlaceboPlacebo (3 mg/kg maltodextrin) | Dietary supplement | Placebo |
Primary outcome
Mean velocity at different %1RM
Time frame: Through study completion, an average of 3 weeks
Mean velocity at different %1RM
Number of repetitions performed during 1 set at 65%1RM until task failure
Time frame: Through study completion, an average of 3 weeks
In bench press and back squat exercises
Bar velocity deplacement performed in 1 set at 65%1RM until task failure
Time frame: Through study completion, an average of 3 weeks
In bench press and back squat exercises
handgrip and isometric mid-thigh pull tests
Time frame: Through study completion, an average of 3 week
N generated
3 secondary outcomes
CYP1A2 polymorphism
Time frame: Before the beginning of the trial
Mood state (tension, depression, anger, vigor, fatigue and confusion)
Time frame: Through study completion, an average of 3 weeks
Adverse effects
Time frame: Through study completion, an average of 3 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: Yes
Related trials for Caffeine
Active, not recruiting
The REVIVE-PEEP Trial: Positive End-expiratory Pressure Versus Sham Valve/Zero End-expiratory Pressure in Cardiopulmonary Resuscitation During Manual Ventilation to Improve Neurological Outcomes at Discharge in Adult Patients Suffering an Out-of-hospital Cardiac Arrest
Cardiac Arrest, Out-Of-Hospital
Recruiting
The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation
Healthy
Active, not recruitingPhase 4
A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising
Exercise
Not yet recruitingPhase 2
CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)
Meconium Aspiration Syndrome
Recruiting
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine in people with Caffeine and Placebo - Control, run by University of Alcala at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean velocity at different %1RM (time frame: Through study completion, an average of 3 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.